Jundishapur Journal of Microbiology

Published by: Kowsar

Th1 Platform Immune Responses Against Leishmania major Induced by Thiol-Specific Antioxidant-Based DNA Vaccines

Fatemeh Tabatabaie 1 , Mehdi Mahdavi 2 , Sobhan Faezi 3 , Abdolhossein Dalimi 4 , Zohreh Sharifi 5 , Lame Akhlaghi 1 and Fatemeh Ghaffarifar 4 , *
Authors Information
1 Department of Parasitology and Mycology, School of Medicine, Iran University of Medical Sciences (IUMS), Tehran, IR Iran
2 Department of Virology, Pasteur Institute of Iran, Tehran, IR Iran
3 Department of Bacteriology, Pasteur Institute of Iran, Tehran, IR Iran
4 Department of Parasitology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, IR Iran
5 Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Tehran, IR Iran
Article information
  • Jundishapur Journal of Microbiology: February 01, 2014, 7 (2); e8974
  • Published Online: February 1, 2014
  • Article Type: Research Article
  • Received: November 20, 2012
  • Revised: January 23, 2013
  • Accepted: February 19, 2013
  • DOI: 10.5812/jjm.8974

To Cite: Tabatabaie F, Mahdavi M, Faezi S, Dalimi A, Sharifi Z, et al. Th1 Platform Immune Responses Against Leishmania major Induced by Thiol-Specific Antioxidant-Based DNA Vaccines, Jundishapur J Microbiol. 2014 ; 7(2):e8974. doi: 10.5812/jjm.8974.

Abstract
Copyright © 2014, Ahvaz Jundishapur University of Medical Sciences. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Materials and Methods
4. Results
5. Discussion
Acknowledgements
Footnotes
References
  • 1. Campos-Neto A, Webb JR, Greeson K, Coler RN, Skeiky YA, Reed SG. Vaccination with plasmid DNA encoding TSA/LmSTI1 leishmanial fusion proteins confers protection against Leishmania major infection in susceptible BALB/c mice. Infect Immun. 2002; 70(6): 2828-36[PubMed]
  • 2. Méndez S, Belkaid Y, Seder RA, Sacks D. Optimization of DNA vaccination against cutaneous leishmaniasis. Vaccine. 2002; 20(31-2): 3702-8[DOI]
  • 3. Webb JR, Campos-Neto A, Ovendale PJ, Martin TI, Stromberg EJ, Badaro R, et al. Human and murine immune responses to a novel Leishmania major recombinant protein encoded by members of a multicopy gene family. Infect Immun. 1998; 66(7): 3279-89[PubMed]
  • 4. Brodskyn C, de Oliveira CI, Barral A, Barral-Netto M. Vaccines in leishmaniasis: advances in the last five years. Expert Rev Vaccines. 2003; 2(5): 705-17[DOI][PubMed]
  • 5. Handman E. Leishmaniasis: current status of vaccine development. Clin Microbiol Rev. 2001; 14(2): 229-43[DOI][PubMed]
  • 6. Mauel J. Vaccination against Leishmania infections. Curr Drug Targets Immune Endocr Metabol Disord. 2002; 2(3): 201-26[PubMed]
  • 7. Mendez S, Gurunathan S, Kamhawi S, Belkaid Y, Moga MA, Skeiky YA, et al. The potency and durability of DNA- and protein-based vaccines against Leishmania major evaluated using low-dose, intradermal challenge. J Immunol. 2001; 166(8): 5122-8[PubMed]
  • 8. Rafati S, Zahedifard F, Nazgouee F. Prime-boost vaccination using cysteine proteinases type I and II of Leishmania infantum confers protective immunity in murine visceral leishmaniasis. Vaccine. 2006; 24(12): 2169-75[DOI][PubMed]
  • 9. Monnerat S, Martinez-Calvillo S, Worthey E, Myler PJ, Stuart KD, Fasel N. Genomic organization and gene expression in a chromosomal region of Leishmania major. Mol Biochem Parasitol. 2004; 134(2): 233-43[DOI][PubMed]
  • 10. Ivory C, Chadee K. DNA vaccines: designing strategies against parasitic infections. Genet Vaccines Ther. 2004; 2(1): 17[DOI][PubMed]
  • 11. Chiang CL, Kandalaft LE, Coukos G. Adjuvants for enhancing the immunogenicity of whole tumor cell vaccines. Int Rev Immunol. 2011; 30(2-3): 150-82[DOI][PubMed]
  • 12. Crowther JR. EISA Theory and Practice. 1995;
  • 13. Zadeh-Vakili A, Taheri T, Taslimi Y, Doustdari F, Salmanian AH, Rafati S. Immunization with the hybrid protein vaccine, consisting of Leishmania major cysteine proteinases Type I (CPB) and Type II (CPA), partially protects against leishmaniasis. Vaccine. 2004; 22(15-16): 1930-40[DOI][PubMed]
  • 14. Campos-Neto A, Porrozzi R, Greeson K, Coler RN, Webb JR, Seiky YA, et al. Protection against cutaneous leishmaniasis induced by recombinant antigens in murine and nonhuman primate models of the human disease. Infect Immun. 2001; 69(6): 4103-8[DOI][PubMed]
  • 15. Tabatabaie F, Dalimi A, Sharifi Z, Hoseini AZ. Cloning and sequencing of Leishmania major thiol-specific-antioxidant antigen (TSA) gene. Iran J Parasitol. 2007; 2(4)
  • 16. Ghaffarifar F, Tabatabaie F, Sharifi Z, Dalimiasl A, Hassan MZ, Mahdavi M. Cloning of a Recombinant Plasmid Encoding Thiol-Specific Antioxidant Antigen (TSA) Gene of Leishmania majorand Expression in the Chinese Hamster Ovary Cell Line. Malays J Med Sci. 2012; 19(1): 15-9[PubMed]
  • 17. Rosado-Vallado M, Mut-Martin M, Garcia-Miss Mdel R, Dumonteil E. Aluminium phosphate potentiates the efficacy of DNA vaccines against Leishmania mexicana. Vaccine. 2005; 23(46-47): 5372-9
  • 18. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Analytical Biochem. 1976; 72(1-2): 248-54[DOI]
  • 19. Buffet PA, Sulahian A, Garin YJ, Nassar N, Derouin F. Culture microtitration: a sensitive method for quantifying Leishmania infantum in tissues of infected mice. Antimicrob Agents Chemother. 1995; 39(9): 2167-8[DOI]
  • 20. Ahmed SB, Bahloul C, Robbana C, Askri S, Dellagi K. A comparative evaluation of different DNA vaccine candidates against experimental murine leishmaniasis due to L. major. Vaccine. 2004; 22(13-14): 1631-9[DOI][PubMed]
  • 21. Rafati S, Salmanian AH, Hashemi K, Schaff C, Belli S, Fasel N. Identification of Leishmania major cysteine proteinases as targets of the immune response in humans. Mol Biochem Parasitol. 2001; 113(1): 35-43[DOI]
  • 22. Webb JR, Kaufmann D, Campos-Neto A, Reed SG. Molecular cloning of a novel protein antigen of Leishmania major that elicits a potent immune response in experimental murine leishmaniasis. J Immunol. 1996; 157(11): 5034-41[PubMed]
  • 23. Coelho EA, Tavares CA, Lima Kde M, Silva CL, Rodrigues JM, Jr., Fernandes AP. Mycobacterium hsp65 DNA entrapped into TDM-loaded PLGA microspheres induces protection in mice against Leishmania (Leishmania) major infection. Parasitol Res. 2006; 98(6): 568-75[DOI][PubMed]
  • 24. Mohammadi MR, Zeinali M, Ardestani SK, Kariminia A. Identification of novel Leishmania major antigens that elicit IgG2a response in resistant and susceptible mice. Korean J Parasitol. 2006; 44(1): 43-8[PubMed]
  • 25. Kenney RT, Sacks DL, Sypek JP, Vilela L, Gam AA, Evans-Davis K. Protective immunity using recombinant human IL-12 and alum as adjuvants in a primate model of cutaneous leishmaniasis. J Immunol. 1999; 163(8): 4481-8[PubMed]
  • 26. Coler RN, Skeiky YA, Bernards K, Greeson K, Carter D, Cornellison CD, et al. Immunization with a polyprotein vaccine consisting of the T-Cell antigens thiol-specific antioxidant, Leishmania major stress-inducible protein 1, and Leishmania elongation initiation factor protects against leishmaniasis. Infect Immun. 2002; 70(8): 4215-25[PubMed]
  • 27. Bivas-Benita M, Bar L, Gillard GO, Kaufman DR, Simmons NL, Hovav AH, et al. Efficient generation of mucosal and systemic antigen-specific CD8+ T-cell responses following pulmonary DNA immunization. J Virol. 2010; 84(11): 5764-74[DOI][PubMed]
  • 28. Kwissa M, Lindblad EB, Schirmbeck R, Reimann J. Codelivery of a DNA vaccine and a protein vaccine with aluminum phosphate stimulates a potent and multivalent immune response. J Mol Med (Berl). 2003; 81(8): 502-10[DOI][PubMed]
  • 29. Gupta R. Aluminum compounds as vaccine adjuvants. Advanced Drug Delivery Rev. 1998; 32(3): 155-72[DOI]
  • 30. Ulmer JB, DeWitt CM, Chastain M, Friedman A, Donnelly JJ, McClements WL, et al. Enhancement of DNA vaccine potency using conventional aluminum adjuvants. Vaccine. 1999; 18(1-2): 18-28[DOI]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments